<DOC>
	<DOCNO>NCT01333696</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety pemetrexed monotherapy salvage treatment patient relapse metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Pemetrexed Salvage Treatment Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>The treatment option patient platinum-resistant relapsed metastatic squamous cell carcinoma head neck limit . Previous randomized phase III study show borderline benefit pemetrexed add cisplatin . Therefore , aim evaluate efficacy pemetrexed salvage setting .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age range : 1865 year old Histological confirm incurable relapse metastatic squamous cell carcinoma head neck Prior exposure least one line platinumcontaining regimen At least one site measurable disease accord RECIST criterion ECOG performance status 01 Life expectancy 3 month Bone marrow function : ANC≧1.5×109/L , PLT≧100×109/L , Hb≧80g/L Liver function : total bilirubin , ALT AST &lt; 1.5×UNL Renal function : Cr &lt; 1.5×UNL , CCR≧45ml/min With curable treatment option Prior platinum exposure neoadjuvant/adjuvant set concurrently use radiotherapy History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Significant active infection Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Squamous cell carcinoma head neck</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>